Table 2: Time Course of T-Cell Subsets After B-Cell Depletion with Rituximab Compared to Baseline

% Before Therapy 1-3 4-6 7-9 10-12
CD3+ 66 ± 10 % 74 ± 11 %* 73 ± 12 %* 73 ± 8 %* 73 ± 8 %*
CD4+ 47 ± 11 % 55 ± 10 %* 51 ± 9 %* 51 ± 10 %* 52 ± 9 %*
CD8+ 26 ± 7 % 25 ± 6 % 28 ± 9 % 27 ± 7 % 26 ± 9 %
CD4+CD25+ 23 ± 8 % 24 ± 13 % 22 ± 8 % 20 ± 7 % 20 ± 10 %
CD3+HLA DR+ 6 ± 5 % 6 ± 7 % 6 ± 5 % 5 ± 3 % 5 ± 4 %
         cells/microlitre
CD3+ 867 ± 537 951 ± 419 923 ± 404 996 ± 584 951 ± 624
CD4+ 630 ± 417 720 ± 299 642 ± 270 718 ± 474 689 ± 475
CD8+ 318 ± 176 304 ± 126 348 ± 161 350 ± 154 324 ± 215
CD4+CD25+ 314 ±196 298 ± 209 265 ± 121 248 ± 108 266 ± 232
CD3+HLA DR+ 69 ± 63 49 ± 25 75 ± 82 59 ± 30 61 ± 68

Relative frequency within lymphocytes and absolute numbers;mean ± SEM
* p < 0.05.